NCT02578680 2024-09-20MK-3475-189Merck Sharp & Dohme LLCPhase 3 Completed616 enrolled 19 charts 1 FDA
NCT00606502 2021-03-05Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based TreatmentSpectrum Pharmaceuticals, IncPhase 2 Completed201 enrolled 12 charts
NCT01165021 2019-09-25A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung CancerEli Lilly and CompanyPhase 2 Completed19 enrolled 14 charts
NCT01999738 2019-02-07Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid TumorsEndocytePhase 1 Completed93 enrolled
NCT00227019 2017-03-06Phase 2 Trial of Bevacizumab in Combination With PemetrexedStanford UniversityPhase 2 Completed16 enrolled 9 charts
NCT00806819 2017-02-02Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLCBoehringer IngelheimPhase 3 Completed718 enrolled 21 charts